475838 | Mifepristone - CAS 84371-65-3 - Calbiochem

475838
Price could not be retrieved
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited Availability Limited Availability
Discontinued
There is a newer version of this product
Limited Quantities Available
Availability to be confirmed
      Will advise
      View Pricing & Availability
         CompareClick To Print This Page

      Overview

      Key Spec Table

      Empirical FormulaCAS #
      C₂₉H₃₅NO₂84371-65-3

      Pricing & Availability

      Catalogue NumberAvailability Packaging Qty/Pack Price Quantity
      475838-50MG
      Retrieving availability...
      Limited Availability Limited Availability
      Discontinued
      There is a newer version of this product
      Limited Quantities Available
      Availability to be confirmed
          Will advise

          50 mg
          Retrieving price...
          Price could not be retrieved
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          Overview A cell-permeable synthetic steroid that acts as a potent antagonist of progesterone and glucocorticoid receptors. Inhibits P-glycoprotein (P-gp) function and down-modulates P-gp mediated drug resistance. Displays anti-angiogenic effects and suppresses vascular endothelial growth factor (VEGF) production. Regulates the expression of Fas and FasL in mouse endometrium and TRAIL in prostate cancer cells. As an antioxidant, it offers neuroprotection against controlled cortical impact (CCI) in CA1 pyramidal cells, as well as Aβ-, H2O2-, and glutamate-induced injury to mouse hippocampal HT22 cells.
          Catalogue Number 475838
          Brand Family Calbiochem®
          Synonyms (11β,17β)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU-486
          References
          References McCullers, D.L., et al. 2002. Neuroscience 109, 219.
          Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
          Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
          Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
          Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
          Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
          Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
          Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
          Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.
          Product Information
          CAS number 84371-65-3
          ATP Competitive N
          Form Yellow solid
          Hill Formula C₂₉H₃₅NO₂
          Chemical formula C₂₉H₃₅NO₂
          Molar Mass 429.6
          Reversible N
          Structure formula Image
          Applications
          Biological Information
          Primary Target Progesterone and glucocorticoid receptors
          Purity ≥99% by titration
          Physicochemical Information
          Cell permeable Y
          Contaminants Steroid substances: ≤0.1%
          Solubility EtOH
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          RTECS KG2955000
          Safety Information
          R Phrase R: 60-61

          May impair fertility.
          May cause harm to the unborn child.
          S Phrase S: 22-36/37/39-45

          Do not breathe dust.
          Wear suitable protective clothing, gloves and eye/face protection.
          In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Carcinogenic / Teratogenic
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze No
          Special Instructions Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          MSDS

          Languages
          Canadian English Canadian-French Ceská Rep
          China China Danmark
          Deutschland Deutschland Eesti
          Ellas English España
          France Iceland Italia
          Korea Latvija Lietuva
          Magyarország Nederland  Norge
          Polska Portugal Srpski
          Standard EU English Suomi Sverige
          Taiwan Thailand US English
          United Kingdom Éire България
          Россия

          Certificates of Analysis

          TitleLot Number
          475838

          References

          Reference overview
          McCullers, D.L., et al. 2002. Neuroscience 109, 219.
          Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
          Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
          Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
          Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
          Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
          Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
          Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
          Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision 28-April-2009 RFH
          Synonyms (11β,17β)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU-486
          Description A cell-permeable, synthetic steroid that acts as a potent antagonist of progesterone and glucocorticoid receptors. Reported to inhibit P-glycoprotein (P-gp) function and down-modulate P-gp mediated drug resistance. Also displays anti-angiogenic effects and suppresses vascular endothelial growth factor (VEGF) production. Shown to regulate the expression of Fas and FasL in mouse endometrium and of TRAIL in prostate cancer cells. As an antioxidant, it is reported to offer neuroprotection against controlled cortical impact (CCI) in CA1 pyramidal cells, as well as Aβ-, H2O2-, and glutamate-induced injury to mouse hippocampal HT22 cells.
          Form Yellow solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number 84371-65-3
          RTECS KG2955000
          Molar mass 429.6
          Chemical formula C₂₉H₃₅NO₂
          Structure formula
          Purity ≥99% by titration
          Contaminants Steroid substances: ≤0.1%
          Solubility Ethanol (10 mg/ml)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze No
          Special Instructions Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Carcinogenic / Teratogenic
          Merck USA index 14, 6186
          References McCullers, D.L., et al. 2002. Neuroscience 109, 219.
          Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
          Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
          Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
          Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
          Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
          Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
          Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
          Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.